HUTCHMED Announces Sovleplenib Granted FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia

Stock News11-05

HUTCHMED (00013) has issued an announcement that sovleplenib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration ("FDA") for the treatment of autoimmune hemolytic anemia.

Sovleplenib is a novel, highly selective oral spleen tyrosine kinase ("Syk") inhibitor. This marks the second FDA Orphan Drug Designation received for sovleplenib, following the orphan drug designation for primary immune thrombocytopenia obtained in October 2026.

The FDA's Orphan Drug Designation program is intended to provide orphan drug status to drugs and biologics that are used for the safe and effective treatment, diagnosis, or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States. If approved by the FDA for the designated indication, a drug granted Orphan Drug Designation is eligible for seven years of U.S. market exclusivity from the date of approval, and may also receive tax credits for qualified clinical trials, exemption from user fees under the Prescription Drug User Fee Act (PDUFA), and specialized regulatory guidance from the FDA during clinical development.

In China, two New Drug Applications for sovleplenib—for the treatment of primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia—are currently under review by the National Medical Products Administration of China. These two applications are based on positive data from the pivotal ESLIM-01 and ESLIM-02 studies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment